Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID‐19

Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID‐19

Abstract ABBV‐47D11 is a neutralizing monoclonal antibody that targets a mutationally conserved hydrophobic pocket distal to the ACE2 binding site of SARS‐CoV‐2. This first‐in‐human safety, pharmacokinetics, and antiviral pharmacodynamic assessment in patients with COVID‐19 provide an initial evalua...

Full description

Bibliographic Details
Main Authors: Mohamad Shebley, Stanley Wang, Izna Ali, Preethi Krishnan, Rakesh Tripathi, Joseph M. Reardon, John Cafardi, Galia Rahav, Yoseph Caraco, Jihad Slim, Fadi Al Akhrass, Mengjia Yu, Yiran Hu, Rosa De Abreu Ferreira, Negar N. Alami
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Pharmacology Research & Perspectives
Subjects:
ABBV‐47D11
COVID‐19
first‐in‐human study
monoclonal antibodies
SARS‐CoV‐2
Online Access:https://doi.org/10.1002/prp2.1036

Internet

https://doi.org/10.1002/prp2.1036

Similar Items